78278343PCR1003

1) Metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate as defined by Prostate Cancer Working Group 3 (PCWG3)

2) Measurable or evaluable disease.

3)
|— a) Part 1A: JNJ-78278343 + cetrelimab – Prior treatment for mCRPC with at least 1 prior androgen receptor pathway inhibitors (ARPI) (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), or chemotherapy (e.g., docetaxel).
|— b) Part 1C: JNJ-78278343 + docetaxel, Part 1D: JNJ-78278343 + apalutamide, Part 1E: JNJ-78278343 + enzalutamide, Part 1F: JNJ-78278343 + darolutamide, and Part 1G: JNJ-78278343 + abiraterone acetate + prednisone – Prior treatment with at least 1 prior ARPI (that is, apalutamide, enzalutamide, darolutamide, or abiraterone acetate,).
|— c) Part 1B: JNJ-78278343 + cabazitaxel – Prior treatment with at least 1 prior ARPI (i.e., abiraterone acetate, apalutamide, enzalutamide, darolutamide) and docetaxel.

4) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

5) Adequate organ functions.

1) Active autoimmune disease within the 12 months prior to signing consent that requires systemic immunosuppressive medications.

2) Toxicity related to prior anticancer therapy that has not returned to Grade less than or equal to (<=) 1 or baseline levels (except for alopecia, vitiligo, Grade <=2 peripheral neuropathy).

3) Solid organ or bone marrow transplantation.

4) Known allergies, or intolerance to any of the components (example, excipients) of JNJ-78278343, cetrelimab (Part 1A), cabazitaxel, (Part 1B), docetaxel (Part 1C), apalutamide (Part 1D), enzalutamide (Part 1E), darolutamide (Part 1F), or abiraterone acetate + prednisone (AAP) (Part 1G).

5) Significant infections or serious lung, heart or other medical conditions.

View more trial information